LobbyingSage Therapeutics lobbying by quarter
Sage Therapeutics's latest lobbying report covers Q4 2024, at $220K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Sage Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $160K | 2 |
| Q1 2023 | $180K | 2 |
| Q2 2023 | $180K | 2 |
| Q3 2023 | $190K | 2 |
| Q4 2023 | $160K | 2 |
| Q1 2024 | $190K | 2 |
| Q2 2024 | $190K | 2 |
| Q3 2024 | $170K | 2 |
| Q4 2024 | $220K | 2 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$833.3K · 18 reports
- Medicare and Medicaid$733.3K · 16 reports
- Budget and appropriations$56.7K · 1 reports
- Homeland security$16.7K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES17 reports
- SENATE17 reports
- Centers For Medicare and Medicaid Services (CMS)7 reports
- Office of the Vice President of the United States3 reports
- Substance Abuse & Mental Health Services Administration (SAMHSA)2 reports
- Centers For Disease Control & Prevention (CDC)1 reports
- Health & Human Services, Dept of (HHS)1 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseSage Therapeutics | $1.2M | 9 quarters |
| Avenue Solutions | $450K | 9 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 25/01/21for Q4 2024 | Avenue Solutions | $50K |
| 25/01/10for Q4 2024 | In-house | $170K |
| 24/10/21for Q3 2024 | Avenue Solutions | $50K |
| 24/10/18for Q3 2024 | In-house | $120K |
| 24/07/22for Q2 2024 | Avenue Solutions | $50K |
| 24/07/19for Q2 2024 | In-house | $140K |
| 24/04/22for Q1 2024 | Avenue Solutions | $50K |
| 24/04/22for Q1 2024 | In-house | $140K |
| 24/01/22for Q4 2023 | Avenue Solutions | $50K |
| 24/01/19for Q4 2023 | In-house | $110K |
| 23/10/20for Q3 2023 | Avenue Solutions | $50K |
| 23/10/18for Q3 2023 | In-house | $140K |
| 23/07/19for Q2 2023 | Avenue Solutions | $50K |
| 23/07/19for Q2 2023 | In-house | $130K |
| 23/04/20for Q1 2023 | Avenue Solutions | $50K |
| 23/04/18for Q1 2023 | In-house | $130K |
| 23/01/20for Q4 2022 | Avenue Solutions | $50K |
| 23/01/19for Q4 2022 | In-house | $110K |
| 23/01/18for Q4 2022 | In-house | $110K |